Antibody Production Shared Resource

基础研究小组 CORE 003-抗体生产共享资源 项目摘要/摘要 在过去的二十年里，从有价值的科学试剂中发展出了关于单抗效用的观点。 包括令人兴奋和有效的疗法。目前已有30多种基于单抗的疗法 在美国和欧洲被批准用于人类，其中近一半是针对癌症的- 相关目标。在癌症研究中，高质量抗体试剂的价值怎么强调都不为过。一个 分子检测的优势部分或完全依赖于高度特异的功能 抗体。尽管商业上可获得的抗体呈爆炸式增长，但相当大的变异性 保留了许多这些试剂的实际特异性和实用性。此外，随着研究的继续， 随着进展，不断出现更具挑战性的抗体需求(修饰特异性抗体， 构象和异构体特异性抗体、功能中和或激活抗体等)。为了这些 原因，范德比尔特-英格拉姆癌症中心(VICC)一直保持和支持着一个充满活力的 抗体开发基础设施。抗体生产共享资源(APSR)提供了全面的 支持各种抗体相关项目的服务(多克隆、单克隆、重组 抗体和抗体工程等)。除了制造抗体外，APSR还继续 扩大其蛋白质生产服务套件，包括抗原和定制的功能重组 蛋白质(例如，生长因子、细胞因子等)。这项服务非常经济高效，为您提供了更多 VICC研究人员获得有价值的试剂并已成功交付关键重组 蛋白质的价格只有商业价格的一小部分。这套强大的蛋白质生产和纯化系统 能力，加上我们的杂交瘤服务，为VICC调查人员提供了独特的能力。这个 建议增加内部兔单克隆抗体的开发、抗体人源化和提供 扩大的抗体和蛋白质试剂目录将进一步增加技术和经济利益 这一设施为VICC研究人员提供。

BASIC RESEARCH GROUP CORE 003 – ANTIBODY PRODUCTION SHARED RESOURCE PROJECT SUMMARY/ABSTRACT Over the past two decades the view of monoclonal antibody utility has grown from valuable scientific reagents to include exciting and potent therapeutics. Over thirty monoclonal antibody–based therapies are now approved for human use in the U.S. and Europe, with nearly one-half of these therapeutics directed at cancer- relevant targets. In cancer research, the value of high-quality antibody reagents is impossible to overstate. A preponderance of molecular assays partially or completely depend upon the function of highly specific antibodies. Though there has been an explosion of commercially available antibodies, considerable variability remains in the actual specificity and utility of many of these reagents. Moreover, as research continues to progress, increasingly more challenging antibody needs continue to emerge (modification-specific antibodies, conformation- and isoform-specific antibodies, functional neutralizing or activating antibodies, etc.). For these reasons, the Vanderbilt-Ingram Cancer Center (VICC) has continuously maintained and supported a vibrant antibody development infrastructure. The Antibody Production Shared Resource (APSR) provides a full range of services supporting all manner of antibody-related projects (polyclonals, monoclonals, recombinant antibodies and antibody engineering, etc.). In addition to making antibodies, the APSR has continued to expand its suite of protein production services to include both antigens and customized functional recombinant proteins (e.g., growth factors, cytokines, etc.). This service is very cost efficient, has opened yet more tools for VICC researchers to obtain valuable reagents and has already successfully delivered critical recombinant proteins at a fraction of the commercial price. This robust suite of protein production and purification capabilities, along with our hybridoma services, provides unique capabilities for the VICC investigators. The proposed additions of in-house rabbit monoclonal antibody development, antibody humanization, and offering an expanded antibody and protein reagent catalog will further add to the technological and economic benefits this facility offers to VICC researchers.